
Research ReportONC
BeiGene (ONC): BRUKINSA Drives a Profitability Inflection
BeiGene has crossed from cash-burning biotech into a profitable global oncology platform, powered by BRUKINSA’s rapid growth and a strengthening balance sheet. The pipeline still matters, but the investment case now rests on commercial execution and self-funding momentum.
Jun 3, 202624 MIN
